- Home
- MPT vs ACAD Comparison
MPT vs ACAD Comparison
Compare MPT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPT | ACAD |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | United States |
| Employees | 118 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | MPT | ACAD |
|---|---|---|
| Price | $5.50 | $22.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 22 |
| Target Price | $5.00 | ★ $30.45 |
| AVG Volume (30 Days) | ★ 6.1M | 1.6M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 6.00% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | N/A | $18.52 |
| Revenue Next Year | $7.14 | $11.34 |
| P/E Ratio | ★ N/A | $9.67 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $5.30 | $14.08 |
| 52 Week High | $6.47 | $28.35 |
Technical Indicators
Market Signals| Indicator | MPT | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 38.07 |
| Support Level | $5.34 | $20.62 |
| Resistance Level | $5.85 | $22.75 |
| Average True Range (ATR) | 0.20 | 1.11 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 12.56 | 12.87 |
Price Performance
Historical ComparisonAbout MPT Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.